Real-world analysis of teclistamab in 123 RRMM patients from Germany.

"Competing interests BB has received honoraria from Janssen and GSK. MB has received speaker honoraria from AstraZeneca and Incyte and travel grants from Janssen. AC received consulting and/or lecture fees from Amgen, Janssen, Pfizer and Takeda and travel and congress participation grants from Janssen. HE has consulted for BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK and Novartis, he has received research funding by BMS/Celgene, Janssen, Amgen, GSK, Sanofi, honoraria from BMS/Celgene, Janssen, Amgen, Takeda, Sanofi, GSK, Novartis and travel support from BMS/Celgene, Janssen, Amgen, Takeda, Novartis, Sanofi. AN has consulted for Celgene, Roche, Takeda, Alexion, Janssen, BMS, Sanofi, Amgen and GSK. He received honoraria from Celgene, Roche, Takeda, Alexion, Janssen, BMS, Sanofi, Amgen, GSK and Jazz and research support from BMS, Janssen and Celgene. KMK received honoraria from from Abbvie, BMS, GSK, Janssen, Pfizer and Takeda. MM has received honoraria from Amgen, Takeda, BMS, Janssen, Stemline and Roche. MSR received honoraria and consulted for Janssen, BMS, Sanofi, Amgen, AbbVie and GSK. RT received honoraria and research funding from Janssen. RW consulted for Amgen, BMS/Celgene, Janssen, Novartis, Kite/Gilead, Pfizer, Sanofi and Takeda, he received research funding from Janssen and Sanofi, and travel support from Janssen, Kite/Gilead, Pfizer and BMS. LR consulted for Janssen, Amgen, GSK, Pfizer, BMS, Sanofi, and received honoraria from Janssen, GSK, Pfizer, BMS, Sanofi and received research funding from Skyline Dx and BMS. CR, FBa, FBr, JFa, JFr, DG, SG-M, MHä, MHo, JK, MK, TL, CM, RM, AM declare no potential competing interests."

"Funding Open Access funding enabled and organized by Projekt DEAL."